These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through affiliate links at no additional cost to the purchaser.

AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...

FluMist is an efficacious and safely tolerated intranasal influenza vaccine. FluMist has gained approval from the FDA for self-administration by patients aged 18-49. FluMist is the first influenza ...

(IN BRIEF) AstraZeneca presented significant advancements ... diff) infections, which can cause severe intestinal issues. In addition, vaccine effectiveness data on FluMist, the only self-administered ...

In September, AstraZeneca's subsidiary MedImmune gained approval for a live H1N1 Flumist vaccine. Further afield, Beijing-based Sinovac Biotech also received approval for an H1N1 vaccine from the ...

If you’re on the fence about investing in AstraZeneca plc (ADR) or Merck & Co Inc because ... Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, ...

LONDON, Nov 12 (Reuters) - London-listed drugmaker AstraZeneca (AZN.L), opens new tab said its plan to invest 450 million ...